Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06867302 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Dexmedetomidine and Agitation After Nasal Surgery

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 1 year 2 months later Sep 1, 2025 → Nov 1, 2026
See other at-risk trials from Fayoum University Hospital

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Sep 1, 2025 to Nov 1, 2026 Show 7 more changesShow less
    • Start date: Mar 1, 2025 to Aug 1, 2025
    • Study completion pushed from Oct 1, 2025 to Dec 1, 2026
    • Interventions: Dexmedetomidine Injection [Precedex] (Drug), Dexmedetomidine in 0.9 % NaCl 1,000 Mcg/250 mL (4 Mcg/mL) INTRAVEN INFUSION BOTTLE (ML) (Drug) to Dexmedetomidine Injection [Precedex] (Drug), Dexmedetomidine in 0.9 % NaCl 1,000 Mcg/250 mL (4 Mcg/mL) INTRAVEN INFUSION BOTTLE (ML) (Drug)
    • Eligibility criteria expanded, about 9 words
    • Secondary endpoints: details revised at 2 of 13 entries
    • Study description revised
    • Publications: details revised at 5 of 5 entries
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The main objective of study is to compare dexmedetomidine single bolus dose before extubation with continuous infusion as regards their efficacy in mitigating the incidence of emergence agitation in obese adults undergoing nasal surgery.
Trial Details
NCT Number NCT06867302
Lead Sponsor Fayoum University Hospital
Conditions
(from sponsor)		 Nasal Disease, Agitation, Emergence
Related terms Emergence Delirium, Nose Diseases
Enrollment 50 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov